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Transposable elements have played a critical role in the creation of new genes in
all higher eukaryotes, including humans. Although the chimeric fusion protein
SETMAR is no longer active as a transposase, it contains both the DNA-binding
domain (DBD) and catalytic domain of the Hsmar1 transposase. The amino-
acid sequence of the DBD has been virtually unchanged in 50 million years and,
as a consequence, SETMAR retains its sequence-specific binding to the
ancestral Hsmar1 terminal inverted repeat (TIR) sequence. Thus, the DNA-
binding activity of SETMAR is likely to have an important biological function.
To determine the structural basis for the recognition of TIR DNA by SETMAR,
the design of TIR-containing oligonucleotides and SETMAR DBD variants,
crystallization of DBD–DNA complexes, phasing strategies and initial phasing
experiments are reported here. An unexpected finding was that oligonucleotides
containing two BrdUs in place of thymidines produced better quality crystals in
complex with SETMAR than their natural counterparts.
1. Introduction
Through a fortuitous sequence of molecular events, SETMAR
arose as a chimeric fusion protein in anthropoid primates
(Cordaux et al., 2006), giving rise to a protein that retains
the lysine methyltransferase activity associated with its SET
domain (Fnu et al., 2011; Carlson et al., 2015) but has lost the
ability to function as a transposase, despite containing an
intact copy of the Hsmar1 DNA tranposon-derived
transposase (Roman et al., 2007; Beck et al., 2011; Liu et al.,
2007; Cordaux et al., 2006; Miskey et al., 2007; Kim et al., 2014;
Robertson & Zumpano, 1997). SETMAR is widely expressed
in a number of human tissues and has been reported to play
a role in DNA double-strand break repair, the restarting
of stalled replication forks and chromosome decatenation
(De Haro et al., 2010; Lee et al., 2005; Shaheen et al., 2010;
Williamson et al., 2008).
The Hsmar1 transposase comprises a DNA-binding domain
(DBD) with two predicted helix–turn–helix (HTH) motifs in
addition to a catalytic domain. The amino-acid sequence of
the DBD is unusually conserved, with only two amino-acid
substitutions in the 50 million years since the ancestralHsmar1
transposon entered the primate lineage downstream of a SET
domain (Robertson & Zumpano, 1997; Cordaux et al., 2006),
and the DBD retains the ability to bind specifically to a 19-
base-pair element within its ancestral terminal inverted repeat
(TIR) sequence. In contrast, the catalytic domain is less well
conserved and harbors 17 amino-acid substitutions compared
with the predicted ancestral sequence (Robertson &
Zumpano, 1997; Cordaux et al., 2006). Importantly, this
ISSN 2053-230X
# 2016 International Union of Crystallography
domain now has a DDN motif in place of the mariner-
associated DDD motif, which is thought to play an important
role in metal binding (Lohe et al., 1997). Thus, the SETMAR
transposase has lost its ancestral site-specific TIR DNA-
cleavage activity and can no longer function as a transposase
(Miskey et al., 2007; Cordaux et al., 2006; Liu et al., 2007).
Restoration of its ancestral transposase activity required
the substitution of 21 amino-acid residues, restoring it to a
consensus sequence with four additional substitutions intro-
duced based on a phylogenetic approach (Miskey et al., 2007).
Crystal structures have been determined for the SET and
transposase catalytic domains, providing a basis for probing
the functions of these two domains (PDB entries 3bo5 and
3k9j, 3k9k and 3f2k, respectively; Structural Genomics
Consortium, unpublished work; Goodwin et al., 2010). Struc-
tures of the catalytic domain have been determined in
complexes with both Ca2+ and Mg2+, each bound to a single
site, suggesting that loss of the third aspartic acid residue may
in fact prevent the binding of a second metal ion involved in
catalysis (Goodwin et al., 2010). To determine the nature of
the interaction of SETMAR with DNA, we sought to crys-
tallize a complex of the DBD bound to both its ancestral TIR
DNA and a sequence variant. Binding to non-TIR DNA
sequences suggests that SETMAR may have evolved to bind
more general sequences within the genome and has implica-
tions for its biological function. Here, we describe the crys-
tallization and initial phasing experiments for SETMAR–
DNA complexes.
2. Materials and methods
2.1. Oligonucleotides and macromolecule production
The oligonucleotides used in this study were purchased
from Midland Certified Reagent (Midland, Texas, USA). They
were synthesized on a 1 mmol scale, desalted and then used
without further purification. A total of eight duplex oligo-
nucleotides were screened in crystallization experiments
(Fig. 1). Stock solutions of 5 mM duplex DNAwere dissolved
and annealed in distilled, deionized water.
For crystallographic studies, two different SETMAR DBD
constructs were used, one including residues 329–440 and the
other residues 316–440. To construct the first construct, DNA
encoding residues 329–671 was PCR-amplified from an
existing pET-15b vector of the SETMAR transposase domain
(Goodwin et al., 2010) and subcloned into the pET-28-derived
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Figure 1
Oligonucleotides used for crystallization trials. Hsmar1 TIR-based DNA
sequences were used for crystallization. The consensus Hsmar1 TIR
sequence is shown for the left TIR element of the predicted ancestral
transposon (top). The italic TA is the characteristic flanking dinucleotide
in the Tc1/mariner transposon superfamily. Oligonucleotides screened
include the 19 bp mariner binding site (shaded in gray) for TIR and the
variant TIR sequences. Boxes indicate overhanging nucleotides expected
to facilitate packing of the DNA in the lattice. Underlined bases indicate
variations from the TIR sequence, and thymidines shown in bold in TIR2
and variant-TIR1 were replaced with bromodeoxyuridines for Br SAD
phasing experiments.
Table 1
Macromolecule-production information.
F indicates forward and R reverse for the primers.
Source organism Human Human
Construct Final 329–440 (first 329–671, then 6His-SUMO-329–440) Final 316–440 (first 316–671, then 6His-SUMO-316–440)
DNA source pET-15b transposase domain of SETMAR (wild type) pFLAG-CMV4 full-length SETMAR (wild type)
329-671_F (left) and 316-671_F
(right) primers
ATATCGGATCCATGAAAATGATGTTAGACAAAAAGCAAATTCG TATATCGGATCCGTGTTCCCCTCCTGCAAGCGATTGA
329-671_R (left) and 316-671_R
(right) primers
TATAGCTCGAGTTAATCAAAATAGGAACCATTACAATC TATAGCTCGAGTTAATCAAAATAGGAACCATTACAATC
DBD_F primer GATATACCATGGGCAGCAGCCATCATCATCATCATC GATATACCATGGGCAGCAGCCATCATCATCATCATC
DBD_R primer TATAGCTCGAGTTACACCTTTCCAATTTGCTTCAAATGTC TATAGCTCGAGTTACACCTTTCCAATTTGCTTCAAATGTC
Cloning vector p6His-SUMO p6His-SUMO
Expression vector p6His-SUMO p6His-SUMO
Expression host E. coli Rosetta (DE3) E. coli Rosetta (DE3)
Complete amino-acid sequence SMKMMLDKKQIRAIFLFEFKMGRKAAETTRNINNAFGPGTANERTVQWW-
FKKFRKGDESLEDEERSGRPSEVDNDQLRAIIEADPLTTTREVAEEL-
NVNHSTVVRHLKQIGKV
SVFPSCKRLTLETMKMMLDKKQIRAIFLFEFKMGRKAAETTRNINNAFG-
PGTANERTVQWWFKKFSKGDESLEDEERSGRPSEVDNDQLRAIIEAD-
PLTTTREVAEELNVNHSTVVRHLKQIGKV
pSUMO vector (Mossessova & Lima, 2000) between BamHI
and XhoI sites (primers 329-671_F and 329-671_R). For the
second construct, DNA encoding residues 316–671 was PCR-
amplified from pFLAG-CMV4 full-length SETMAR (wild
type; Beck et al., 2008) and subcloned into the pSUMO vector
between BamHI and XhoI sites (primers 316-671_F and 316-
671_R). Since the DNA encoding the DBD is about 300 bp, in
order to ease the purification of the PCR product by gel
extraction, the forward primer was designed to include the
N-terminal 6His-SUMO tag-coding region in the pET-28-
derived pSUMO vector. Using primers DBD_F and DBD_R,
DNA encoding 6His-SUMO-SETMAR (amino acids 329–
440) or 6His-SUMO-SETMAR (amino acids 316–440) was
PCR-amplified from the cognate plasmid encoding residues
329–671 or 316–671, respectively, and subcloned into pSUMO
vector between NcoI and XhoI sites. The primers used for
subcloning are listed in Table 1. In this study, all primers were
purchased from Integrated DNA Technologies Inc. (Coral-
ville, Iowa, USA). The final plasmids were verified by DNA
sequencing (Genewiz Inc., South Plainfield, New Jersey,
USA). To optimize the crystallization conditions, C381R and
C381S mutations were generated individually using the
QuikChange II site-directed mutagenesis kit (Agilent Tech-
nologies, Santa Clara, California, USA). Primers for site-
directed mutagenesis are shown in Supplementary Table S1.
The DBDs of SETMAR used in this study, including resi-
dues 329–440 or 316–440 and various substituted versions of
these constructs, were expressed and purified as described
previously (Kim et al., 2014). For selenomethionine (SeMet)
protein constructs, double mutations (I359M and L423M)
were introduced into the 329–440(C381R) plasmid to generate
the pET-28b-SUMO-SETMAR-329-440(C381R)(I359M)(L423M)
construct using the QuikChange II site-directed mutagenesis
kit (Agilent Technologies, Santa Clara, California, USA). The
primers used to introduce additional methionines are shown in
Supplementary Table S1. SeMet protein was expressed using
an protocol adapted from the literature (Van Duyne et al.
1993). Escherichia coli Rosetta cells (EMD Millipore,
Billerica, Massachusetts, USA) were grown in M9 minimal
medium. At an OD of 0.5–0.6, an amino-acid cocktail solution
(Lys, Phe and Thr at 100 mg per litre of culture; Ile, Leu and
Val at 50 mg per litre of culture) was added to inhibit
methionine synthesis. Selenomethionine was supplied to the
medium to a final concentration of 60 mg l1. Cells were
induced by addition of 1 mM IPTG and were grown at 18C
overnight. The SeMet protein-purification protocol is the
same as that for the wild-type protein. In brief, following lysis
and centrifugation, the cell lysate was applied onto an Ni–
NTA column and then subjected to on-column cleavage with
the SUMO-specific Ulp1 protease to remove the N-terminal
His-SUMO affinity tag. The eluent was then applied onto a
tandem Q Sepharose/SP Sepharose column; the protein was
eluted from the SP Sepharose column, subjected to size-
exclusion chromatography (SEC) and then concentrated to
approximately 5 mM for storage in 50 mM HEPES pH 7.5,
500 mM NaCl, 1 mM DTT at 80C.
2.2. Crystallization
All of the DBD variants were mixed with duplex DNA
(5 mM stock) to give a final protein:DNA molar ratio of 1:1.2
in 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT and
incubated on ice for 15 min prior to crystallization. The
resulting protein concentration was 500 mM. Initial crystal-
lization screens were performed using a Gryphon crystal-
lization robot (Art Robbins Instruments, Sunnyvale,
California, USA) with 0.6 ml drops (0.3 ml complex solution
plus 0.3 ml reservoir solution) and 60 ml reservoirs in 96-well
sitting-drop vapor-diffusion plates (Intelli-Plate 96-3 LVR,
Hampton Research, Aliso Viejo, California, USA). Subse-
quently, all crystals were grown by vapor diffusion in 2 ml (1 ml
complex solution plus 1 ml reservoir solution) hanging drops at
20C suspended over 500 ml reservoir solution. The crystals for
data collection were obtained by microseeding, cryoprotected
in a solution containing 20% ethylene glycol and flash-cooled
in liquid nitrogen before data collection. Crystallization
information is summarized in Table 2.
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Table 2
Crystallization.
ND, not determined.
Protein–DNA complex DBD (329–440)–TIR2
DBD (329–440)
(C381S)–TIR2
DBD (329–440)
(C381S)–variant TIR1
DBD (316–440)
(C381S)–variant TIR1
DBD (329–440)
(C381R)–TIR2
Method Vapor diffusion Vapor diffusion Vapor diffusion Vapor diffusion Vapor diffusion
Image Figs. 2(a) and 2(b) Fig. 2(c) Fig. 2(d) Fig. 2(e) Fig. 2( f )
Plate type VDX VDX VDX VDX VDX
Temperature (K) 293 293 293 293 293
Protein concentration 0.5 mM:0.6 mM 0.5 mM:0.6 mM 0.5 mM:0.6 mM 0.5 mM:0.6 mM 0.5 mM:0.6 mM
Buffer composition of
protein solution
50 mM HEPES pH 7.5,
150 mM NaCl,
1 mM DTT
50 mM HEPES pH 7.5,
150 mM NaCl,
1 mM DTT
50 mM HEPES pH 7.5,
150 mM NaCl,
1 mM DTT
50 mM HEPES pH 7.5,
150 mM NaCl,
1 mM DTT
50 mM HEPES pH 7.5,
150 mM NaCl,
1 mM DTT
Composition of reservoir
solution
0.2M Li2SO4,
0.1M bis-tris pH 5.5,
25%(w/v) PEG 3350
25% poly(acrylic acid
sodium) 5100,
0.10M HEPES pH 7.5,
0.02M MgCl2
0.01M Mg(CH3COO)2,
0.05M MES pH 5.6,
2.5M (NH4)2SO4
0.10M Mg(HCO2)2,
15% PEG 3350
0.025M MgSO4 hydrate,
0.05M Tris–HCl pH 8.5,
1.8M (NH4)2SO4
Volume and ratio of drop 2 ml, 1:1 2 ml, 1:1 2 ml, 1:1 2 ml, 1:1 2 ml, 1:1
Volume of reservoir (ml) 0.5 0.5 0.5 0.5 0.5
Space group ND C2 ND C2221 C2221
2.3. Data collection and processing
Data were collected using a MAR Mosaic CCD on the
GM/CA 23-ID-B beamline and were processed using an
automated script with XDS (Kabsch, 2010), POINTLESS
(Evans, 2006) and AIMLESS (Evans & Murshudov, 2013).
Statistics for data processing and scaling are shown in Table 3.
3. Results and discussion
3.1. Variation of the protein and DNA components of the
complex
The ability to crystallize protein–DNA complexes involving
a small DBD relative to the size of the DNA depends critically
on optimizing both the protein and DNA components of the
complex. In this study, we began with the wild-type SETMAR
DBD including residues 329–440 based on a sequence
comparison with the related transposase Mos1. Using SEC,
the SETMAR DBD was found to elute as a single peak
(Supplementary Fig. S1). Addition of TIR DNA to SETMAR
DBD results in the formation of a complex which elutes at a
higher molecular weight following SEC (Supplementary Fig.
S1), consistent with tight binding. An apparent Kd of 3 nM for
the binding of SETMAR DBD to TIR DNA was determined
by fluorescence polarization (Kim et al., 2014).
Four different complexes including DBD 329–440 and one
of the four TIR oligonucleotides (Fig. 1) were screened in
crystallization trials. The four TIR-containing oligonucleo-
tides were designed based on prior knowledge of the Hsmar1
binding site within the TIR (Cordaux et al., 2006) and the
available crystal structures of Tc3 and Mos1 complexed with
DNA (Watkins et al., 2004; Richardson et al., 2009). In these
initial designs, the placement of the 19 bp mariner binding site
(MBS) relative to the ends of the oligonucleotides and the
length of the duplex regions was varied. The DNA sequences
include two 24-mer duplexes with one 50 overhanging
nucleotide on each strand, TIR1 and TIR3, and two 25-mer
duplexes with one 50 overhanging nucleotide, TIR2 and TIR4.
In TIR1, the 19 bp MBS was placed centrally with three
additional 50 nucleotides from the TIR sequence and two
nucleotides 30 to the recognition element. TIR3 included two
50 nucleotides and three 30 nucleotides on either side of the
MBS. TIR2 included four 50 nucleotides and two 30 nucleo-
tides, and TIR4 two 50 nucleotides and four 30 nucleotides.
Either G:C or A:T overhangs were screened for these two
positions of the MBS.
To identify crystallization conditions, approximately 400
conditions contained within the Index, Natrix, Natrix 2,
Crystal Screen, Crystal Screen 2, PEG/Ion and PEG/Ion 2 kits
(Hampton Research) were screened. Crystals were obtained
for the complex of DBD 329–440 with TIR2 from Index
condition G2: 0.2M Li2SO4, 0.1M bis-tris pH 5.5, 25% PEG
3350. These crystals grew primarily in layers with few single
crystals but diffracted to approximately 8 A˚ resolution
(Fig. 2a, Supplementary Fig. S2a). Using freshly purified
protein we were able to reproduce these crystals, but not with
protein that had been stored even for a few days. However, we
found that the addition of TCEP resulted in much larger single
crystals that could be reproduced with stored protein (Fig. 2b);
these crystals also diffracted X-rays to about 8 A˚ resolution
(Supplementary Fig. S2b).
Since TCEP is highly effective at keeping sulfhydryls
reduced, thus limiting disulfide-bond formation, we then
looked for cysteine residues in the protein sequence that
might form intermolecular disulfide bonds during the crys-
tallization process and identified one Cys residue, Cys381,
within this DBD. The equivalent position in Mos1 is Lys54,
which is solvent-exposed in the crystal structure of the paired-
end Mos1 complex (Richardson et al., 2009). Interestingly, it
was this same cysteine that was substituted with Arg, together
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Table 3
Data collection and processing.
Values in parentheses are for the outer shell.
Crystal DBD 329–440 (C381R)–TIR2 DBD 329–440 (C381R)–TIR2 Blended data
Diffraction source GM/CA 23-ID-B GM/CA 23-ID-B GM/CA 23-ID-B
Wavelength (A˚) 0.97945 0.97945 0.97945
Temperature (K) 93 93 93
Detector MAR Mosaic CCD MAR Mosaic CCD MAR Mosaic CCD
Crystal-to-detector distance (mm) 350 350 350
Rotation range per image () 0.5 0.5 NA
Total rotation range () 140 140 NA
Exposure time per image (s) 2 2 NA
Space group C2221 C2221 C2221
a, b, c (A˚) 72.41, 167.01, 66.61 71.63, 166.29, 65.40 72.02, 166.65, 66.01
, ,  () 90, 90, 90 90, 90, 90 90, 90, 90
Mosaicity () 0.31 0.80 NA
Resolution range (A˚) 47.04–3.75 (4.19–3.75) 83.14–3.24 (3.5–3.24) 46.71–4.17 (4.67–4.17)
Total No. of reflections 48084 70866 67781
No. of unique reflections 4262 6468 3177
Completeness (%) 98.0 (98.7) 99.6 (97.0) 99.9 (100.0)
Multiplicity 11.3 (11.5) 11.0 (11.2) 21.3 (22.3)
hI/(I)i 13.0 (3.0) 10.8 (2.8) 20.5 (10.7)
Rmeas 0.162 (1.066) 0.215 (1.199) 0.158 (0.476)
Overall B factor from Wilson plot (A˚2) 98.12 76.55 109.20
with other critical substitutions, to reconstruct an active
Hsmar1 transposase from the human genome (Miskey et al.,
2007). Thus, we introduced two different substitutions for
Cys381: C381S, representing a relatively conservative substi-
tution, and C381R, as found in the revertant Hsmar1. We then
screened DBD 329–440 (C381S) complexed with each
of the four TIR oligonucleotides. Crystals of DBD 329–440
(C381S) complexed with TIR2 were obtained from Index
condition E11 consisting of 25% poly(acrylic acid sodium)
5100, 0.10MHEPES pH 7.5, 0.02MMgCl2 (Fig. 2c), and were
similar in morphology to those of the wild-type DBD–TIR2
complex grown in the presence of TCEP. A very small cryo-
cooled crystal diffracted X-rays to 4 A˚ resolution and
belonged to the monoclinic space group C2, with unit-cell
parameters a = 78.7, b = 168.6, c = 74.9 A˚,  = 108.35. In this
case, attempts to cryocool larger crystals were unsuccessful,
with diffraction limited to low resolution. In screening DBD
329–440 (C381R) complexed with each of the first four
oligonucleotides (Fig. 1), crystals were obtained for a complex
with TIR2 from Natrix condition D9, which consists of
0.025M magnesium sulfate hydrate, 0.05M Tris–HCl pH 8.5,
1.8M ammonium sulfate (Fig. 2f). The crystals obtained with
the natural DNA sequence diffracted to 4 A˚ resolution
(Supplementary Fig. S2d) and belonged to space group C2221,
with unit-cell parameters a = 74.73, b = 168.76, c = 72.19 A˚.
Another variable screened with the goal of improving the
crystals was the sequence of the DNAused for crystallization.
Nucleotides within the TIR2 DNA sequence that were not
critical for SETMAR binding in the reported EMSA analysis
were substituted to create variant TIR sequences (Fig. 1). Our
screen of these variant TIR oligonucleotides complexed with
DBD 329–440 (C381S) produced crystals with variant TIR1 in
Natrix condition A2, which consists of 0.01M magnesium
acetate, 0.05M MES pH 5.6, 2.5M ammonium sulfate
(Fig. 2d). However, cryocooling this crystal form proved to
be problematic, as indicated by the low-resolution X-ray
diffraction images. Interestingly, no promising crystals were
obtained from DBD 329–440 (C381R) with the variant TIR1
complex.
In the process of molecular domestication of the Hsmar1
transposase gene downstream of the SET gene, a previously
noncoding sequence between these two current exons was
converted to encode a linker region. This linker region of the
DBD N-terminal extension might fold back to interact with
the minor groove and provide another DNA-interacting
element, as seen in the Tc3–DNA complex (Watkins et al.,
2004). To explore this possibility in SETMAR, we made a
DBD protein including residues 316–440, 14 amino acids
longer than the 329–440 construct, and screened this DBD
with each of the eight oligonucleotides (Fig. 1). Crystals were
obtained for a complex including DBD 316–440 (C381S) with
variant TIR1 in 0.10M magnesium formate, 15% PEG 3350
(Fig. 2e). An initial diffraction image for this crystal is shown
in Supplementary Fig. S2(c). Later, improved crystals of DBD
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Figure 2
Crystal images of initial crystallization trials. (a) DBD 329–440 (wild type) with TIR2. (b) DBD 329–440 (wild type) with TIR2 with TCEP additive. (c)
DBD 329–440 (C381S) with TIR2. (d) DBD 329–440 (C381S) with variant TIR1. (e) DBD 316–440 (C381S) with variant TIR1. ( f ) DBD 329–440
(C381R) with TIR2.
316–440 (C381S) with variant TIR1 diffracted to 3.15 A˚
resolution and belonged to space group C2221, with unit-cell
parameters a = 72.23, b = 164.39, c = 67.96 A˚.
A total of four TIR-derived sequences and four variant TIR
sequences were used for crystallization trials in complexes
with the following DBD constructs: 329–440, 329–440 (C381S),
329–440 (C381R) and 316–440 (C381S) (Fig. 1). The DBD–
DNA complexes that ultimately resulted in usable diffraction
quality crystals were DBD 329–440 (C381R)–TIR2 and DBD
316–440 (C381S)–variant TIR1.
3.2. Considerations in phasing strategies
Although the DBDs of SETMAR and Mos1 are 30%
identical, the DNA-recognition sequences for each protein
are unrelated. This is relevant because the DNA makes up
approximately 55% of the mass of the complex. Thus, we
pursued two single anomalous dispersion (SAD) phasing
strategies: Se SAD and Br SAD. Since three of the four
intrinsic Met residues are clustered at the N-terminus and are
likely to be disordered, we sought to improve the Se signal by
increasing the number of ordered SeMet residues within the
protein for experimental Se SAD phasing purposes. Through
a sequence comparison with the related transposase Mos1,
we identified conserved Leu or Ile residues within -helical
regions of HTH1 and HTH2 motifs in Mos1 that might be well
ordered and tolerate substitution by Met to improve the Se
anomalous signal (Supplementary Fig. S3). Four doubly
mutated constructs were made including the following pairs:
L343M and L404M, L343M and L423M, I359M and L404M,
and I359M and L423M. The double-mutant protein constructs
were introduced into the 329–440 (C381R) plasmid. Of these,
DBD 329–440 (C381R)(I359M)(L423M) was stably expressed
in sufficient quantities for crystallization experiments. With
the introduction of two additional methionines, there are a
total of six possible Se sites in the SeMet-labeled protein
(Supplementary Fig. S3).
SETMAR DBD 329–440 (C381R) and SeMet-substituted
DBD were subjected to analysis on an Agilent 6520 Q-TOF
(quadrupole time-of-flight) mass spectrometer, which has a
mass accuracy of 1 Da, to ensure that the SeMet-substituted
protein had been produced (Supplementary Fig. S4). The
calculated mass for the native DBD 329–440 (C381R) is
13 078.8 Da and that observed was 13 079.06 Da. For the
SeMet protein, the largest peak observed had a mass of
13 397.17 Da, consistent with the expected mass of
13 396.52 Da for the incorporation of six SeMet residues in
place of the four native methionines and two additional Met
substitutions.
For Br SAD experimental phasing, two thymidines (dT)
were replaced with Br-dU in two strands for TIR2 and within a
single strand for variant TIR1, with the criteria that those sites
were not symmetrically positioned within the oligonucleotide
and would not be expected to be in direct contact with the
protein based on prediction (Fig. 1). To confirm the presence
of Br in the crystals, we measured several X-ray absorption
scans. An example is shown in Supplementary Fig. S5 for the
variant TIR1 crystals, with a peak at 13 487.52 eV, consistent
with spectra for brominated DNA (Supplementary Fig. S5).
Data were collected for both variant TIR and TIR complexes
to 3.1 and 2.8 A˚ resolution, respectively. As analyzed in HKL-
3000, there was no observable anomalous signal for the DBD
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Figure 3
Preliminary low-resolution electron-density map of a SETMAR DBD–DNA complex. (a) Experimental electron-density map phased at 4.2 A˚
resolution. Phases were calculated from three Se positions from data combined in BLEND from two SeMet-derivative crystals. (b) An initial phosphate
backbone model is shown with the experimental density map.
329–440 (C381R)–TIR complex and a very weak signal for
the DBD 316–440 (C381S)–variant TIR1 complex at 4.5 A˚.
Attempts to obtain a good solution for the Br sites at many
different resolutions were unsuccessful, and electron-density
maps phased from the sites of these solutions were unin-
terpretable. Although Br SAD phasing experiments were not
successful, crystals grown for DBD complexes with bromin-
ated oligonucleotides were uniformly of better quality than
those grown for the corresponding complex with the natural
DNA sequences. As a consequence, all of the crystals used for
phasing experiments contained brominated oligonucleotides.
We can only speculate that differences in the solubility or
purity of these oligonucleotides contributed to the improved
crystal quality.
3.3. Low-resolution Se SAD phasing
Two data sets were collected on beamline 23-ID-D at the
Advanced Photon Source for SeMet-derivatized DBD 329–
440 (C381R)(I359M)(L423M) complexed with brominated
TIR2 DNA: one to 3.75 A˚ resolution and one to 3.24 A˚
resolution (Table 3). Attempts to identify Se sites from either
data set alone were not successful. Therefore, using BLEND
(Foadi et al., 2013), the two SeMet SAD data sets were
merged, producing a 4.2 A˚ resolution data set. Three of the
possible six sites were identified using AutoSol as imple-
mented in PHENIX (Adams et al., 2010), namely I359M,
L423M and the intrinsic Met348. These sites were used to
phase an electron-density map at 4.2 A˚ resolution (Fig. 3). The
electron density of the DNA phosphate backbone was iden-
tified in this map, and an initial model for the DNA phosphate
backbone and a polyalanine model for the two HTH motifs
were built. Having completed these initial experiments, we
optimized the crystallization of SeMet-substituted DBD 329–
440 (C381R)(I359M)(L423M) complexed with Br-dU TIR2
oligonucleotides and ultimately obtained crystals that
diffracted to higher resolution and completed a structure
determination, which will be reported elsewhere.
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